Kusumoto, Takeru

No ORCID on file · 12 papers in corpus · active 2021

Study types

  • article 10
  • other 2

Condition tags

  • endometriosis 12
  • dysmenorrhea 4
  • dyspareunia 4
article 2021
Additional file 1 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821126

Additional file 1. Demographic and baseline characteristics.

article 2021
Additional file 1 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821126.v1

Additional file 1. Demographic and baseline characteristics.

article 2021
Additional file 2 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821129.v1

Additional file 2. Change from baseline in mean of M-B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.

article 2021
Additional file 2 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821129

Additional file 2. Change from baseline in mean of M-B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.

article 2021
Additional file 3 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821132

Additional file 3. Change from baseline in mean of B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.

article 2021
Additional file 3 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821132.v1

Additional file 3. Change from baseline in mean of B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.

article 2021
Additional file 4 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821135

Additional file 4. Results of other endpoints.

article 2021
Additional file 4 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821135.v1

Additional file 4. Results of other endpoints.

article 2021
Additional file 5 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821141

Additional file 5. Summary of pharmacodynamic parameters at each assessment point.

article 2021
Additional file 5 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.14821141.v1

Additional file 5. Summary of pharmacodynamic parameters at each assessment point.

other 2021
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.c.5477380.v1

Abstract Background Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. Method…

other 2021
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
·doi:10.6084/m9.figshare.c.5477380

Abstract Background Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. Method…